Literature DB >> 26418204

Predictors of Thromboembolic Events in Patients with Ventricular Assist Device.

Amelia K Boehme1, Salpy V Pamboukian, James F George, Chrisly Dillon, Emily B Levitan, Russell Griffin, T Mark Beasley, Gerald McGwin, James K Kirklin, Nita A Limdi.   

Abstract

Ventricular assist device patients (VAD) are at increased risk for thromboembolism. Biomarkers of hemolysis, such as lactate dehydrogenase (LDH) and poorly controlled international normalized ratio (INR) has been identified as predictors of thromboembolism. Patients aged 19 years and older who had a continuous flow VAD placed from 2006 to 2012 were included in this study (N = 115). We assessed the relationship of LDH elevation (≥600 IU/L) at different time points and thromboembolism. Over the 51.3 person-years of follow-up, a total of 23 first thromboembolic events occurred. Patients with elevated LDH on the day of VAD implantation had an increased risk for thromboembolism (hazard ratio [HR]: 4.72, 95% confidence interval [CI]: 1.44-15.4; p = 0.01). There was an increased risk of thromboembolism with early LDH elevation within the first month post-VAD (HR: 4.95, 95% CI: 1.69-14.4; p = 0.003) and estimated glomerular filtration rate <30 before VAD implantation (HR: 4.74, 95% CI: 1.12-20.1; p = 0.0346), whereas there was a decreased risk with good anticoagulation control (HR: 0.30, 95% CI: 0.10-0.86; p = 0.0247). Our study is the first to highlight the association between LDH elevation on the day of implantation and post-VAD thromboembolism. This study details the increased risk of thromboembolism with early LDH elevation and the importance of maintaining time in therapeutic INR range.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26418204      PMCID: PMC4631630          DOI: 10.1097/MAT.0000000000000284

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  24 in total

Review 1.  New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.

Authors:  Jack Ansell
Journal:  Circulation       Date:  2012-01-03       Impact factor: 29.690

2.  Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

Authors:  Jack Ansell; Jennifer Hollowell; Vittorio Pengo; Fernando Martinez-Brotons; Jaime Caro; Ludovic Drouet
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

3.  When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.

Authors:  S-M Huang; R Temple; S Xiao; L Zhang; L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2009-11       Impact factor: 6.875

4.  Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices.

Authors:  Farhan Majeed; Willem J Kop; Robert S Poston; Seeta Kallam; Mandeep R Mehra
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-02

5.  Unexpected abrupt increase in left ventricular assist device thrombosis.

Authors:  Randall C Starling; Nader Moazami; Scott C Silvestry; Gregory Ewald; Joseph G Rogers; Carmelo A Milano; J Eduardo Rame; Michael A Acker; Eugene H Blackstone; John Ehrlinger; Lucy Thuita; Maria M Mountis; Edward G Soltesz; Bruce W Lytle; Nicholas G Smedira
Journal:  N Engl J Med       Date:  2013-11-27       Impact factor: 91.245

6.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Authors:  Gregory Y H Lip; Robby Nieuwlaat; Ron Pisters; Deirdre A Lane; Harry J G M Crijns
Journal:  Chest       Date:  2009-09-17       Impact factor: 9.410

7.  Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation.

Authors:  Andrew J Boyle; Stuart D Russell; Jeffrey J Teuteberg; Mark S Slaughter; Nader Moazami; Francis D Pagani; O Howard Frazier; Gerald Heatley; David J Farrar; Ranjit John
Journal:  J Heart Lung Transplant       Date:  2009-09       Impact factor: 10.247

8.  Chronic kidney disease increases risk for venous thromboembolism.

Authors:  Keattiyoat Wattanakit; Mary Cushman; Catherine Stehman-Breen; Susan R Heckbert; Aaron R Folsom
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

9.  Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation.

Authors:  John M Stulak; Salil Deo; John Schirger; Keith D Aaronson; Soon J Park; Lyle D Joyce; Richard C Daly; Francis D Pagani
Journal:  Ann Thorac Surg       Date:  2013-09-12       Impact factor: 4.330

10.  Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis.

Authors:  Ruth Dubin; Mary Cushman; Aaron R Folsom; Linda F Fried; Walter Palmas; Carmen A Peralta; Christina Wassel; Michael G Shlipak
Journal:  BMC Nephrol       Date:  2011-01-26       Impact factor: 2.388

View more
  2 in total

1.  Impact of time in therapeutic range after left ventricular assist device placement: a comparison between thrombus and thrombus-free periods.

Authors:  Julia C Lea; Catherine K Floroff; Amanda I Ingemi; Gary R Zeevi
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 2.  Hypertension and Stroke in Patients with Left Ventricular Assist Devices (LVADs).

Authors:  Joshua Z Willey; Amelia K Boehme; Francesco Castagna; Melana Yuzefpolskaya; A Reshad Garan; Veli Topkara; Paolo C Colombo
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.